Semarion Secures $3.8 Million to Scale Next-Generation Cell Assay Technology and Accelerate Pharma Adoption

Tuesday, March 31, 2026

AI Briefing

Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption.
The company was founded by combining materials engineering and cell biology at the University of Cambridge's Cavendish Laboratory.
The fundraise was led by Parkwalk and joined by multiple investors to support commercial expansion.